The company is not selling any of its common stock pursuant to this prospectus, and will not receive any proceeds from the sale of its common stock offered by this prospectus by the selling stockholders.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
- Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating
- Surrozen Focuses on Ophthalmology Amid Financial Challenges
- Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year
- Surrozen Secures $76.4M in Private Placement Deal
- Surrozen to focus Wnt expertise, technologies on ophthalmology programs